Medindia

X

Gleevec Increases Survival Times in Patients With GIST

by Kathy Jones on  June 6, 2011 at 6:31 PM Cancer News   - G J E 4
Using Novartis' cancer drug Gleevec for up to three years after surgery, instead of the commonly followed practice of just one year, could increase the survival period of patients suffering from gastrointestinal stromal tumors (GIST).
 Gleevec Increases Survival Times in Patients With GIST
Gleevec Increases Survival Times in Patients With GIST
Advertisement

The study, led by Dr Heikki Joensuu from University of Helsinki, Finland, found that taking Gleevec for three years after surgery increased the five year survival chances of the patients by 55 percent compared to those who took the drug for just one year.

Advertisement
Over 400 patients took part in the study that was presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The researchers found that at the end of five years, more than 65 percent of those who had taken the drug for three years were cancer-free compared to 48 percent of those who took it for one year.

"I tend to think three year treatment will be the standard. I think these data are pretty compelling", Joensuu said.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All